Casey  Lynch net worth and biography

Casey Lynch Biography and Net Worth

CEO of Cortexyme
Casey C. Lynch has served as our President and Chief Executive Officer and a member of our board of directors since July 2014, and as Chairman of our board of directors since November 2018. Ms. Lynch has served on the board of directors of Longboard Pharmaceuticals since February 2021. Prior to co-founding Cortexyme, Ms. Lynch co-founded and led various companies and organizations in the biotechnology industry including Aspira Biosystems, Inc. and NeuroInsights, LLC. She served as Aspira’s co-founder, President and Chief Executive Officer from 1999 to 2004 and she co-founded NeuroInsights, LLC and served as its Managing Director from 2004 to 2015. Ms. Lynch also co-founded the Neurotechnology Industry Organization and served as a board member from March 2005 to September 2018. Ms. Lynch oversaw toxicology screening and evaluated new product opportunities at Centaur Pharmaceuticals, including multiple sclerosis, arthritis, and uveitis. Ms. Lynch conducted preclinical testing for Alzheimer’s disease treatment at the Wadsworth Medical Center and researched the neurological basis of schizophrenia and epilepsy at UCLA. Her graduate work on neurotrophic factor cell biology and neurodegenerative diseases, was carried out at UCSF and Stanford University. Ms. Lynch holds a B.S. in Neuroscience from the University of California, Los Angeles, an M.S. in Neuroscience from the University of California, San Francisco.

What is Casey Lynch's net worth?

The estimated net worth of Casey Lynch is at least $91,806.80 as of May 10th, 2021. Ms. Lynch owns 49,895 shares of Cortexyme stock worth more than $91,807 as of November 21st. This net worth estimate does not reflect any other investments that Ms. Lynch may own. Learn More about Casey Lynch's net worth.

How do I contact Casey Lynch?

The corporate mailing address for Ms. Lynch and other Cortexyme executives is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. Cortexyme can also be reached via phone at (650) 910-5717 and via email at [email protected]. Learn More on Casey Lynch's contact information.

Has Casey Lynch been buying or selling shares of Cortexyme?

Casey Lynch has not been actively trading shares of Cortexyme during the last quarter. Most recently, Casey Lynch sold 30,000 shares of the business's stock in a transaction on Monday, May 10th. The shares were sold at an average price of $34.58, for a transaction totalling $1,037,400.00. Following the completion of the sale, the chief executive officer now directly owns 49,895 shares of the company's stock, valued at $1,725,369.10. Learn More on Casey Lynch's trading history.

Who are Cortexyme's active insiders?

Cortexyme's insider roster includes Michael Detke (Insider), Stephen Dominy (Insider), David Lamond (Director), Christopher Lowe (CFO), Casey Lynch (CEO), and Margaret Mcloughlin (Director). Learn More on Cortexyme's active insiders.

Casey Lynch Insider Trading History at Cortexyme

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2021Sell30,000$34.58$1,037,400.0049,895View SEC Filing Icon  
3/22/2021Sell30,000$35.59$1,067,700.0049,895View SEC Filing Icon  
2/3/2021Sell20,000$43.03$860,600.0049,895View SEC Filing Icon  
2/1/2021Sell20,000$36.25$725,000.0049,895View SEC Filing Icon  
See Full Table

Casey Lynch Buying and Selling Activity at Cortexyme

This chart shows Casey Lynch's buying and selling at Cortexyme by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cortexyme Company Overview

Cortexyme logo
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $1.84
Low: $1.77
High: $1.87

50 Day Range

MA: $1.07
Low: $0.69
High: $1.95

2 Week Range

Now: $1.84
Low: $1.78
High: $40.66

Volume

140,411 shs

Average Volume

620,672 shs

Market Capitalization

$55.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4